Clinical evaluation of a GP5+/6+-based luminex assay having full high-risk human papillomavirus genotyping capability and an internal control

Journal of Clinical Microbiology

Volumn 52, Issue 11, 2014, Pages 3996-4002

  Geraets, D T ^a   Cuschieri, K ^b   De Koning, M N C ^a   Van Doorn, L J ^a   Snijders, P J F ^c   Meijer, C J L M ^c   Quint, W G V ^a   Arbyn, M ^d  

^a Manager Development and Diagnostic Services (DDS)   (Netherlands)

^b ROYAL INFIRMARY OF EDINBURGH   (United Kingdom)

^c VU UNIVERSITY MEDICAL CENTER   (Netherlands)

^d SCIENTIFIC INSTITUTE OF PUBLIC HEALTH   (Belgium)

Author keywords

[No Author keywords available]

Indexed keywords

ADULT; AGED; ARTICLE; CANCER GRADING; CANCER SCREENING; CLINICAL EVALUATION; CONTROLLED STUDY; DIAGNOSTIC KIT; DIAGNOSTIC TEST ACCURACY STUDY; ENZYME IMMUNOASSAY; FEMALE; FOLLOW UP; GENOTYPE; HIGH RISK PATIENT; HUMAN; HUMAN PAPILLOMAVIRUS DNA TEST; INFECTION RISK; LUMINEX ASSAY; MAJOR CLINICAL STUDY; NONHUMAN; PAPILLOMAVIRUS INFECTION; POLYMERASE CHAIN REACTION; RISK ASSESSMENT; RISK FACTOR; SCREENING TEST; SENSITIVITY ANALYSIS; SENSITIVITY AND SPECIFICITY; UTERINE CERVIX CARCINOMA IN SITU; UTERINE CERVIX CYTOLOGY; VIRUS DETECTION; VIRUS EXAMINATION; VIRUS GENOME; YOUNG ADULT; CLASSIFICATION; COMPARATIVE STUDY; EARLY DIAGNOSIS; EVALUATION STUDY; GENETICS; ISOLATION AND PURIFICATION; MIDDLE AGED; MOLECULAR DIAGNOSIS; OLIGONUCLEOTIDE PROBE; PAPILLOMAVIRIDAE; PAPILLOMAVIRUS INFECTIONS; PATHOLOGY; PROCEDURES; STANDARD; STANDARDS; UTERINE CERVIX; VIROLOGY;

OLIGONUCLEOTIDE PROBE;

ADULT; CERVICAL INTRAEPITHELIAL NEOPLASIA; CERVIX UTERI; EARLY DETECTION OF CANCER; FEMALE; HUMANS; MIDDLE AGED; MOLECULAR DIAGNOSTIC TECHNIQUES; OLIGONUCLEOTIDE PROBES; PAPILLOMAVIRIDAE; PAPILLOMAVIRUS INFECTIONS; REFERENCE STANDARDS; SENSITIVITY AND SPECIFICITY; YOUNG ADULT;

EID: 84908315997     PISSN: 00951137     EISSN: 1098660X     Source Type: Journal    
DOI: 10.1128/JCM.01962-14     Document Type: Article

References (36)

1. Bouvard V, Baan R, Straif K, Grosse Y, Secretan B, El Ghissassi F, Benbrahim-Tallaa L, Guha N, Freeman C, Galichet L, Cogliano V, WHO International Agency for Research on Cancer Monograph Working Group. 2009. A review of human carcinogens - part B: biological agents. Lancet Oncol. 10:321-322. http://dx.doi.org/10.1016/S1470-2045(09)70096-8.
2. Sankaranarayanan R, Nene BM, Shastri SS, Jayant K, Muwonge R, Budukh AM, Hingmire S, Malvi SG, Thorat R, Kothari A, Chinoy R, Kelkar R, Kane S, Desai S, Keskar VR, Rajeshwarkar R, Panse N, Dinshaw KA. 2009. HPV screening for cervical cancer in rural India. N. Engl. J. Med. 360:1385-1394. http://dx.doi.org/10.1056/NEJMoa0808516.
3. Kitchener HC, Almonte M, Thomson C, Wheeler P, Sargent A, Stoykova B, Gilham C, Baysson H, Roberts C, Dowie R, Desai M, Mather J, Bailey A, Turner A, Moss S, Peto J. 2009. HPV testing in combination with liquid-based cytology in primary cervical screening (ARTISTIC): a randomised controlled trial. Lancet Oncol. 10:672-682. http://dx.doi.org/10.1016/S1470-2045(09)70156-1.
4. Ronco G, Giorgi-Rossi P, Carozzi F, Confortini M, Dalla Palma P, Del Mistro A, Ghiringhello B, Girlando S, Gillio-Tos A, De Marco L, Naldoni C, Pierotti P, Rizzolo R, Schincaglia P, Zorzi M, Zappa M, Segnan N, Cuzick J. 2010. Efficacy of human papillomavirus testing for the detection of invasive cervical cancers and cervical intraepithelial neoplasia: a randomised controlled trial. Lancet Oncol. 11:249-257. http://dx.doi.org/10.1016/S1470-2045(09)70360-2.
5. Hesselink AT, Bulkmans NW, Berkhof J, Lorincz AT, Meijer CJ, Snijders PJ. 2006. Cross-sectional comparison of an automated hybrid capture 2 assay and the consensus GP5+/6+ PCR method in a population-based cervical screening program. J. Clin. Microbiol. 44:3680-3685. http://dx.doi.org/10.1128/JCM.02078-05.
6. Naucler P, Ryd W, Tornberg S, Strand A, Wadell G, Elfgren K, Radberg T, Strander B, Forslund O, Hansson BG, Hagmar B, Johansson B, Rylander E, Dillner J. 2009. Efficacy of HPV DNA testing with cytology triage and/or repeat HPV DNA testing in primary cervical cancer screening. J. Natl. Cancer Inst. 101:88-99. http://dx.doi.org/10.1093/jnci/djn444.
7. Bulkmans NW, Rozendaal L, Snijders PJ, Voorhorst FJ, Boeke AJ, Zandwijken GR, van Kemenade FJ, Verheijen RH, v Groningen K, Boon ME, Keuning HJ, van Ballegooijen M, van den Brule AJ, Meijer CJ. 2004. POBASCAM, a population-based randomized controlled trial for implementation of high-risk HPV testing in cervical screening: design, methods and baseline data of 44,102 women. Int. J. Cancer 110:94-101. http://dx.doi.org/10.1002/ijc.20076.
8. Bulkmans NW, Berkhof J, Rozendaal L, van Kemenade FJ, Boeke AJ, Bulk S, Voorhorst FJ, Verheijen RH, van Groningen K, Boon ME, Ruitinga W, van Ballegooijen M, Snijders PJ, Meijer CJ. 2007. Human papillomavirus DNA testing for the detection of cervical intraepithelial neoplasia grade 3 and cancer: 5-year follow-up of a randomised controlled implementation trial. Lancet 370:1764-1772. http://dx.doi.org/10.1016/S0140-6736(07)61450-0.
9. Rijkaart DC, Berkhof J, Rozendaal L, van Kemenade FJ, Bulkmans NW, Heideman DA, Kenter GG, Cuzick J, Snijders PJ, Meijer CJ. 2012. Human papillomavirus testing for the detection of high-grade cervical intraepithelial neoplasia and cancer: final results of the POBASCAM randomised controlled trial. Lancet Oncol. 13:78-88. http://dx.doi.org/10.1016/S1470-2045(11)70296-0.
10. Arbyn M, Ronco G, Anttila A, Meijer CJ, Poljak M, Ogilvie G, Koliopoulos G, Naucler P, Sankaranarayanan R, Peto J. 2012. Evidence regarding human papillomavirus testing in secondary prevention of cervical cancer. Vaccine 30(Suppl 5):F88-F99. http://dx.doi.org/10.1016/j.vaccine.2012.06.095.
11. Meijer CJ, Berkhof J, Castle PE, Hesselink AT, Franco EL, Ronco G, Arbyn M, Bosch FX, Cuzick J, Dillner J, Heideman DA, Snijders PJ. 2009. Guidelines for human papillomavirus DNA test requirements for primary cervical cancer screening in women 30 years and older. Int. J. Cancer 124:516-520. http://dx.doi.org/10.1002/ijc.24010.
12. Depuydt CE, Benoy IH, Beert JF, Criel AM, Bogers JJ, Arbyn M. 2012. Clinical validation of a type-specific real-time quantitative human papillomavirus PCR against the performance of hybrid capture 2 for the purpose of cervical cancer screening. J. Clin. Microbiol. 50:4073-4077. http://dx.doi.org/10.1128/JCM.01231-12.
13. Ejegod DM, Serrano I, Cuschieri KS, Nussbaumer WA, Vaughan LM, Ahmad AS, Cuzick J, Bonde J. 2013. Clinical validation of the BD Onclarity HPV assay using a non-inferiority test. Med. Microbiol. Diagn. S3:003.
14. Hesselink AT, Berkhof J, van der Salm ML, van Splunter AP, Geelen TH, van Kemenade FJ, Bleeker MG, Heideman DA. 2014. Clinical validation of the HPV-risk assay, a novel real-time PCR assay for detection of high-risk human papillomavirus DNA by targeting the E7 region. J. Clin. Microbiol. 52:890-896. http://dx.doi.org/10.1128/JCM.03195-13.
15. Cox JT, Castle PE, Behrens CM, Sharma A, Wright TC, Jr, Cuzick J, Athena HPV Study Group. 2013. Comparison of cervical cancer screening strategies incorporating different combinations of cytology, HPV testing, and genotyping for HPV 16/18: results from the ATHENA HPV study. Am. J. Obstet. Gynecol. 208:184.e1-184.e11. http://dx.doi.org/10.1016/j.ajog.2012.11.020.
16. Khan MJ, Castle PE, Lorincz AT, Wacholder S, Sherman M, Scott DR, Rush BB, Glass AG, Schiffman M. 2005. The elevated 10-year risk of cervical precancer and cancer in women with human papillomavirus (HPV) type 16 or 18 and the possible utility of type-specific HPV testing in clinical practice. J. Natl. Cancer Inst. 97:1072-1079. http://dx.doi.org/10.1093/jnci/dji187.
17. Kjaer S, Hogdall E, Frederiksen K, Munk C, van den Brule A, Svare E, Meijer C, Lorincz A, Iftner T. 2006. The absolute risk of cervical abnormalities in high-risk human papillomavirus-positive, cytologically normal women over a 10-year period. Cancer Res. 66:10630-10636. http://dx.doi.org/10.1158/0008-5472.CAN-06-1057.
18. Bulk S, Bulkmans NW, Berkhof J, Rozendaal L, Boeke AJ, Verheijen RH, Snijders PJ, Meijer CJ. 2007. Risk of high-grade cervical intraepithelial neoplasia based on cytology and high-risk HPV testing at baseline and at 6-months. Int. J. Cancer 121:361-367. http://dx.doi.org/10.1002/ijc.22677.
19. de Sanjose S, Quint WG, Alemany L, Geraets DT, Klaustermeier JE, Lloveras B, Tous S, Felix A, Bravo LE, Shin HR, Vallejos CS, de Ruiz PA, Lima MA, Guimera N, Clavero O, Alejo M, Llombart-Bosch A, Cheng-Yang C, Tatti SA, Kasamatsu E, Iljazovic E, Odida M, Prado R, Seoud M, Grce M, Usubutun A, Jain A, Suarez GA, Lombardi LE, Banjo A, Menendez C, Domingo EJ, Velasco J, Nessa A, Chichareon SC, Qiao YL, Lerma E, Garland SM, Sasagawa T, Ferrera A, Hammouda D, Mariani L, Pelayo A, Steiner I, Oliva E, Meijer CJ, Al-Jassar WF, Cruz E, Wright TC, et al. 2010. Human papillomavirus genotype attribution in invasive cervical cancer: a retrospective crosssectional worldwide study. Lancet Oncol. 11:1048 -1056. http://dx.doi.org/10.1016/S1470-2045(10)70230-8.
20. Halfon P, Lindemann ML, Raimondo A, Ravet S, Camus C, Khiri H, Penaranda G, Sideri M, Sandri MT. 2013. HPV genotype distribution according to severity of cervical neoplasia using the Digene HPV genotyping LQ test. Arch. Virol. 158:1143-1149. http://dx.doi.org/10.1007/s00705-012-1584-4.
21. Cuzick J, Ho L, Terry G, Kleeman M, Giddings M, Austin J, Cadman L, Ashdown-Barr L, Costa MJ, Szarewski A. 2014. Individual detection of 14 high risk human papilloma virus genotypes by the PapType test for the prediction of high grade cervical lesions. J. Clin. Virol. 60:44-49. http://dx.doi.org/10.1016/j.jcv.2014.02.002.
22. Meijer CJ, Snijders PJ, Castle PE. 2006. Clinical utility of HPV genotyping. Gynecol. Oncol. 103:12-17. http://dx.doi.org/10.1016/j.ygyno.2006.07.031.
23. Geraets DT, Heideman DA, de Koning MN, Snijders PJ, van Alewijk DC, Meijer CJ, van Doorn LJ, Quint WG. 2009. High-throughput genotyping of high-risk HPV by the digene HPV genotyping LQ test using GP5+/6+-PCR and xMAP technology. J. Clin. Virol. 46(Suppl 3):S21-S26. http://dx.doi.org/10.1016/S1386-6532(09)70297-5.
24. Geraets DT, Lenselink CH, Bekkers RL, van Doorn LJ, Quint WG, Melchers WJ. 2011. Universal human papillomavirus genotyping by the digene HPV genotyping RH and LQ tests. J. Clin. Virol. 50:276-280. http://dx.doi.org/10.1016/j.jcv.2010.12.011.
25. Geraets DT, van Baars R, Alonso I, Ordi J, Torne A, Melchers WJ, Meijer CJ, Quint WG. 2013. Clinical evaluation of high-risk HPV detection on self-samples using the indicating FTA-elute solid-carrier cartridge. J. Clin. Virol. 57:125-129. http://dx.doi.org/10.1016/j.jcv.2013.02.016.
26. Godínez JM, Tous S, Baixeras N, Moreno-Crespi J, Alejo M, Lejeune M, Bravo IG, Bosch FX, de Sanjosé S. 2011. Performance of the digene LQ, RH and PS HPVs genotyping systems on clinical samples and comparison withHC2and PCR-based linear array. Infect. Agent Cancer 6:23. http://dx.doi.org/10.1186/1750-9378-6-23.
27. Ogilvie GS, Cook DA, Taylor DL, Rank C, Kan L, Yu A, Mei W, van Niekerk DJ, Coldman AJ, Krajden M. 2013. Population-based evaluation of type-specificHPVprevalence among women in British Columbia, Canada. Vaccine 31:1129-1133. http://dx.doi.org/10.1016/j.vaccine.2012.09.085.
28. Arbyn M, Steben M. 2010. Highlights of the 26th international papillomavirus conference and workshops. Future Oncol. 6:1711-1724. http://dx.doi.org/10.2217/fon.10.136.
29. Evans DM, Hudson EA, Brown CL, Boddington MM, Hughes HE, Mackenzie EF, Marshall T. 1986. Terminology in gynaecological cytopathology: report of the Working Party of the British Society for Clinical Cytology. J. Clin. Pathol. 39:933-944. http://dx.doi.org/10.1136/jcp.39.9.933.
30. Arbyn M, Herbert A, Schenck U, Nieminen P, Jordan J, McGoogan E, Patnick J, Bergeron C, Baldauf JJ, Klinkhamer P, Bulten J, Martin-Hirsch P. 2007. European guidelines for quality assurance in cervical cancer screening: recommendations for collecting samples for conventional and liquid-based cytology. Cytopathology 18:133-139. http://dx.doi.org/10.1111/j.1365-2303.2007.00464.x.
31. Arbyn M, Anttila A, Jordan J, Ronco G, Schenck U, Segnan N, Wiener H, Herbert A, von Karsa L. 2010. European Guidelines for Quality Assurance in Cervical Cancer Screening. Second edition-summary document. Ann. Oncol. 21:448-458. http://dx.doi.org/10.1093/annonc/mdp471.
32. Richart RM. 1973. Cervical intraepithelial neoplasia. Pathol. Annu. 8:301-328.
33. Caballero OL, Villa LL, Simpson AJ. 1995. Low stringency-PCR (LSPCR) allows entirely internally standardized DNA quantitation. Nucleic Acids Res. 23:192-193. http://dx.doi.org/10.1093/nar/23.1.192.
34. van Doorn LJ, Molijn A, Kleter B, Quint W, Colau B. 2006. Highly effective detection of human papillomavirus 16 and 18 DNA by a testing algorithm combining broad-spectrum and type-specific PCR. J. Clin. Microbiol. 44:3292-3298. http://dx.doi.org/10.1128/JCM.00539-06.
35. Cuzick J, Clavel C, Petry KU, Meijer CJ, Hoyer H, Ratnam S, Szarewski A, Birembaut P, Kulasingam S, Sasieni P, Iftner T. 2006. Overview of the European and North American studies on HPV testing in primary cervical cancer screening. Int. J. Cancer 119:1095-1101. http://dx.doi.org/10.1002/ijc.21955.
36. Söderlund-Strand A, Kjellberg L, Dillner J. 2014. Human papillomavirus type-specific persistence and recurrence after treatment for cervical dysplasia. J. Med. Virol. 86:634-641. http://dx.doi.org/10.1002/jmv.23806.